ArticleJCO precision oncology2018
Clinical Utility of Rapid
Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Precision oncology at speed: workflow design determines clinical utility in rapid molecular testing for lung cancer.The oncologist · 2026Article
- A Decadal Bibliometric Analysis of Circulating Tumor DNA (ctDNA) Research in Lung Cancer (2012-2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- TPM3-NTRK1 fusion confers resistance to osimertinib in lung adenocarcinoma: a model in a continuous cell line.Human cell · 2025Article
- Integrating ctDNA testing forAdvances in laboratory medicine · 2025Review
- Article
- Oncogene-driven lung cancer in the era of radiogenomics: current evidence and future developments.Discover oncology · 2025Review
- Administrative Alignment for Integrated Diagnostics Leads to Shortened Time to Diagnose and Service Optimization.Radiology · 2024Article
- Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib.JCO oncology practice · 2023Article
- Recent advances in non-small cell lung cancer targeted therapy; an update review.Cancer cell international · 2023Review
- Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study.Respiratory research · 2023Review
- Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform.Current oncology (Toronto, Ont.) · 2022Article
- Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing.Journal of personalized medicine · 2022Review
- Article
- Article
- Contribution of the IdyllaCurrent oncology (Toronto, Ont.) · 2021Article
- Rapid non-destructive volumetric tumor yield assessment in fresh lung core needle biopsies using polarization sensitive optical coherence tomography.Biomedical optics express · 2021Article
- Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation.Current oncology (Toronto, Ont.) · 2021Article
- Targeted Assessment of theCancers · 2020Article
- Imaging Features and Metastatic Patterns of AdvancedAJR. American journal of roentgenology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 1 institution in 1 country.
Funding
Abstract
purposeTargeted therapy is the cornerstone of treatment of advanced PATIENTS AND
methodsWe performed rapid testing for
resultsBetween January 2015 and September 2017, we performed 243 rapid
conclusionRapid genotyping facilitates earlier initiation of EGFR-directed therapies without compromising NGS workflows.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.